| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Entry into a Material Definitive Agreement
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
First patient dosed in Phase 1b of DUET study evaluating SZN-8141 in patients with diabetic macular edema |
| 20 Oct 2026 |
8-K: Results of Operations and Financial Condition; Unregistered Sales of Equity Securities
Proceeds strengthen balance sheet and provide expected cash runway into 2029 to advance SZN-8141 and SZN-8143 |
| 02 Oct 2026 |
8-K: Other Events
On October 2, 2026, Surrozen, Inc. (Surrozen) announced U.S. Food and Drug Administration (FDA) clearance of our Investigational New Drug (IND) application for SZN-8141, enabling us to advance the program into clinical development. The I... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 |
| 14 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 13, 2026, Surrozen, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (“Annual Meeting”). A total of 11,486,707 shares of the Company’s common stock were entitled to vote as of March 18, 2026, the record date for t... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 |
| 23 Mar 2026 |
8-K: Results of Operations and Financial Condition
Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 |
| 30 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On January 26, 2026, Shao-Lee Lin, M.D., Ph.D. resigned from the Board of Directors of Surrozen, Inc., or the Company, effective immediately. Dr. Lin’s resignation was not because of any disagreement with the Company on any matter relati... |
| 07 Nov 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
SOUTH SAN FRANCISCO, Calif., November 7, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue ... |
| 17 Oct 2025 |
8-K: Termination of a Material Definitive Agreement
On October 14, 2025, Surrozen, Inc. (the “Company”) received notice from TCGFB, Inc. (“TCGFB”) that TCGFB has elected to terminate the Collaboration Agreement (the “Collaboration Agreement”) between TCGFB and the Company, dated October 3... |
| 29 Aug 2025 |
8-K: Entry into a Material Definitive Agreement
Surrozen, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: |
| 08 Aug 2025 |
8-K: Results of Operations and Financial Condition
Daniel Chao, M.D., Ph.D., joins Surrozen as Vice President of Clinical Development |
| 15 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 14, 2025, Surrozen, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (“Annual Meeting”). A total of 3,281,169 shares of the Company's common stock were entitled to vote as of March 19, 2025, the record date for th... |
| 09 May 2025 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., May 9, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repai... |
| 31 Mar 2025 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regen... |
| 28 Mar 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Securities Purchase Agreement (this “Agreement”) is dated as of March 24, 2025, by and between Surrozen, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto and set forth on Anne... |
| 24 Mar 2025 |
8-K: Regulation FD Disclosure
Legal Disclaimers This presentation contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential... |
| 06 Nov 2024 |
8-K: Results of Operations and Financial Condition
Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 2025 |
| 02 Oct 2024 |
8-K: Entry into a Material Definitive Agreement
This FIRST AMENDMENT TO LEASE (“First Amendment”) is made and entered into as of 10/1/2024, by and between HCP OYSTER POINT III LLC, a Delaware limited liability company (“Landlord”) and SURROZEN OPERATING, INC., a Delaware corporation (... |
Loading...